EicOsis
Davis
About EicOsis
EicOsis is developing inhibitors to a the soluble epoxide hydrolase, a key regulatory enzyme involved in the metabolism of fatty acids, to treat unmet medical needs in human and animals.sEH inhibitors treat pain by stabilizing natural analgesic and anti-inflammatory mediators.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $10.0M
- Last round: Grant (Mar 2019)
- Website: eicosis.com
- Phone: 650 455 0388
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/eicosis-143389 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.